---
title: "此次收購可能意味著在即將發布的中期業績中，領展進一步擴大回購規模的空間已收窄。 — 瑞銀 — DecisionGateway"
description: "prediction by 瑞銀, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1e6ae-dba1-7ae2-b9a4-6bb09a2d5422"
meta:
  "og:description": "prediction by 瑞銀, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "此次收購可能意味著在即將發布的中期業績中，領展進一步擴大回購規模的空間已收窄。 — 瑞銀 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

prediction

# **此次收購可能意味著在即將發布的中期業績中，領展進一步擴大回購規模的空間已收窄。**

A prediction by [**瑞銀**](https://dgw.tmarket.io/actors/01a1d49e-d995-7396-8810-d1e55c335b54). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *此次收購可能意味著在即將發布的中期業績中，領展進一步擴大回購規模的空間已收窄。*

stockintelligencenewsPublished 2026-11-11 [ Read source](https://t.me/stockintelligencenews/5715681)

[**瑞銀 dossier **](https://dgw.tmarket.io/actors/01a1d49e-d995-7396-8810-d1e55c335b54)

## **Discussion**

## **Related claims**

[**交易預計於明年首季完成，領展將透過內部資源及債務融資支付收購代價。**領展資產管理 · prediction](https://dgw.tmarket.io/claims/01a1e67b-941f-7d99-b093-a60674bc75fc) [**考慮到領展過往在併購方面的表現參差不齊，投資者或許會質疑此次收購及未來潛在的收購能否真正創造可持續的股東價值。**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e6ae-dbc9-7e04-b2e8-7f8b52bd08e4) [**瑞銀表示，考慮到領展過往在併購方面的表現參差不齊，投資者或許會質疑此次收購及未來潛在的收購能否真正創造可持續的股東價值。**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e72b-f470-7d72-adcc-1ae3bd208989) [**交易完成後，領展將於新加坡管理三個零售資產，包括東福坊、裕廊坊及宏茂橋坊。**領展房產基金 · prediction](https://dgw.tmarket.io/claims/01a1e6bf-f464-7699-b81a-5e4660024fbf) [**交易完成後，領展將於新加坡管理3個零售資產，包括東福坊、裕廊坊及宏茂橋坊。**信報 · prediction](https://dgw.tmarket.io/claims/01a1e794-e14a-754a-a10e-73b2d14e4f62) [**交易完成後，領展將於新加坡管理三個零售資產，包括東福坊、裕廊坊及宏茂橋坊。**領展 · prediction](https://dgw.tmarket.io/claims/01a1e67b-947a-7c70-8e8d-b128fdbcf72c)

## **More claims by 瑞銀**

[**Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.**prediction](https://dgw.tmarket.io/claims/01a1e751-3094-73c5-92e4-9c2e1b97e4fa) [**Tigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.**statement](https://dgw.tmarket.io/claims/01a1e751-3083-714b-9c7b-13200f21418b) [**If the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.**prediction](https://dgw.tmarket.io/claims/01a1e751-306d-78f1-ac3c-2b57bdf9bbb3) [**Frontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.**statement](https://dgw.tmarket.io/claims/01a1e751-3054-7ca0-a7ed-2ee97b0ffbc4) [**After the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.**statement](https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df)

[All claims by 瑞銀](https://dgw.tmarket.io/claims?claimant_id=01a1d49e-d995-7396-8810-d1e55c335b54)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts — every claim cited to its public source. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1e6ae-dba1-7ae2-b9a4-6bb09a2d5422#webpage","@type":"WebPage","description":"prediction by 瑞銀, recorded recently — verbatim quote and source citation.","name":"此次收購可能意味著在即將發布的中期業績中，領展進一步擴大回購規模的空間已收窄。 — 瑞銀 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1e6ae-dba1-7ae2-b9a4-6bb09a2d5422","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1e6ae-dba1-7ae2-b9a4-6bb09a2d5422#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1e6ae-dba1-7ae2-b9a4-6bb09a2d5422"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1e6ae-dba1-7ae2-b9a4-6bb09a2d5422#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"此次收購可能意味著在即將發布的中期業績中，領展進一步擴大回購規模的空間已收窄。","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1e6ae-dba1-7ae2-b9a4-6bb09a2d5422#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-11","isBasedOn":"https://t.me/stockintelligencenews/5715681","text":"此次收購可能意味著在即將發布的中期業績中，領展進一步擴大回購規模的空間已收窄。","url":"/claims/01a1e6ae-dba1-7ae2-b9a4-6bb09a2d5422","spokenByCharacter":{"@type":"Person","name":"瑞銀","@id":"/actors/01a1d49e-d995-7396-8810-d1e55c335b54"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.
